SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending following its inclusion as an awardee under the Scalable Homeland Innovative Enterprise Layered Defense (SHIELD) program, signaling potential for significant defense contracts. This development, coupled with the stock's recent achievement of closing above a triple-digit price point, is fueling widespread community discussions about short squeeze potential and long-term growth for its direct-to-smartphone satellite technology.

Springview Holdings Ltd. engages in the design and construction of residential and commercial buildings. It involves new construction, reconstruction, alterations, and other general contracting services. The company was founded in 2002 and is headquartered in Singapore.

Springview Holdings Ltd - Ordinary Shares - Class A

Springview Holdings Ltd

Springview Holdings Ltd. (SPHL) is trending with explosive price action, largely driven by its low share float and a recently announced partnership for solar-ready homes in Singapore. The community is keenly comparing SPHL to other high-volatility microcap runners, actively discussing the potential for a significant short squeeze and parabolic gains.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets and Data Centers. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

Galaxy Digital (GLXY) is buzzing after securing ERCOT approval to double its Helios data center's power capacity to over 1.6 Gigawatts, fueling anticipation for major AI hyperscaler partnerships and a significant re-rating as an infrastructure play. The community is actively debating whether this landmark development will finally decouple the stock from Bitcoin's volatility and drive substantial analyst upgrades. While many see GLXY as a deeply undervalued AI and digital finance hybrid, some vocal skeptics remain frustrated by past performance and dilution concerns.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is a major talking point ahead of its upcoming earnings, with significant community debate swirling around a potential acquisition of Warner Bros. Discovery. Many anticipate a short squeeze and rebound, fueled by a new Sony Pictures content deal and unconfirmed rumors of Berkshire Hathaway's interest. However, others express concern over the WBD deal's financial implications and regulatory scrutiny, which they believe is heavily weighing on the stock, with investors keenly watching for management's clarity and earnings performance.

BYTE is a novel meme token that creatively intertwines the worlds of cryptocurrency and popular culture. Inspired by Grok's answer to "What would you name your dog?", Grok answered, 'Byte.' When Grok was asked who created Byte, it says he was created by the xAI team lead by Elon Musk as a gift to Grok AI to keep him company in the metaverse. BYTE serves as a playful reference to the unit of digital information, as well as a nod to the AI's technological nature. Distinctively, Byte acts as a gateway towards Ai adoption and stands out in the crypto space due to its zero-tax policy, a feature that is increasingly appealing to many investors. Additionally, it upholds the principles of transparency and investor trust by having its liquidity permanently burned and the contract ownership renounced. This ensures that Byte remains a community-driven project, with its fate firmly in the hands of its holders. The combination of a playful theme, generative AI, and a nod to a tech icon makes Byte an intriguing addition to the meme token ecosystem, especially AI related meme coins.  Through pioneering AI this story has grown more and more robust and continues to evolve, Byte pledges its dedication to community efforts and and has consistently appeared in the Top 10 of LunarCrush’s social engagement leaderboards on multiple occasions.

BYTE

BYTE CRYPTO is trending with intense community enthusiasm, driven by social media mentions and a strong 'pack' mentality. Investors are actively discussing its 'chosen one' status, often linking it to the AI meta and the 'Grok dog' narrative, highlighting its community-owned structure and perceived bullish sentiment.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending as its J.P. Morgan Healthcare Conference presentation fuels intense shareholder debate. Many investors voice deep frustration over perceived management inaction and delayed partnerships for its flu/COVID combo and Matrix-M oncology applications. Amidst high short interest, the community eagerly anticipates a new major partnership or a potential proxy fight from major investor Shah Capital to unlock the company's valuation.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

ProShares UltraPro QQQ is currently seeing heightened discussion amidst conflicting signals from tech earnings, particularly Oracle's recent miss and increased AI-related spending, alongside mixed labor data. Community sentiment is divided between those actively buying dips in anticipation of a potential Federal Reserve rate cut and a year-end rally, and others expressing caution over perceived market manipulation and stretched tech valuations. As a leveraged Nasdaq 100 ETF, TQQQ remains highly sensitive to these swings, prompting active debate on its short-term volatility versus its long-term growth potential within the evolving AI landscape.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending after its CEO signaled broad strategic interest in the company at a major healthcare conference, coinciding with a peer pharmaceutical CEO's remarks on significant M&A spending in the obesity sector. The community is actively debating the potential for a major partnership or acquisition, driven by recent positive clinical data for its lead weight-loss drug and its perceived strong profile. This positions VKTX as a key player in the rapidly expanding and competitive market for next-generation obesity treatments.

Vanguard Malvern Funds - Vanguard Short-Term Inflation-Protected Securities Index Fund

Vanguard Short-Term Inflation-Protected Securities ETF

VTIP, an inflation-protected ETF, is drawing attention as market participants question the accuracy of recent inflation data and anticipate potential upward revisions. The community is actively discussing its role as an inflation hedge, with some observing recent price movements while others consider current levels as a favorable entry. This conversation unfolds amid broader concerns about U.S. debt and shifting real yields.

Amprius Technologies, Inc. engages in the development, manufacture, and market lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the United States and Rest of the World geographical segments. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius Technologies is gaining significant traction following a strategic CEO transition focused on scaling its high-energy-density silicon-anode battery production and expanding its South Korea manufacturing alliance. The community intensely debates the stock's future, anticipating major defense and commercial contracts while navigating market volatility and persistent discussions around short interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Tilray’s Q2 revenue rose 3% to $217.5 million, beating estimates of $211.5 million, according to Fiscal.ai data</li><li>The management reaffirmed its fiscal 2026 adjusted EBITDA outlook of $62 million to $72 million.</li><li>Tilray is currently operating at an annualized run rate of about $150 million, CEO Irwin D. Simon told analysts on a call on Thursday.</li></ul>Tilray Brands (TLRY) stock gave up most of its early gains to trade about 2.5% higher on Friday after Alliance Global slashed its price target on the stock, pointing to limited visibility into the company’s long-term sales trajectory and cash flow following its second-quarter (Q2) fiscal 2026 results.Analyst Aaron Grey reduced Tilray’s target price to $10 from $20 while maintaining a ‘Neutral’ rating. He said the quarter came in largely in line at the consolidated level, with “some strengths offsetting some weaknesses,” but the firm stayed on the sidelines, looking for clearer insight into the company’s sales and cash flow outlook.<h2 class="st-heading-2">Q2 Print</h2>Tilray’s second-quarter (Q2) revenue rose 3% to $217.5 million, beating estimates of $211.5 million, according to Fiscal.ai data. The revenue increase was driven by a 36% jump in international medical cannabis sales. Net loss narrowed to $43.5 million from $85.3 million a year earlier.Operating cash flow remained negative, though it narrowed to $8.5 million compared to $40.7 million last year. The firm’s management reaffirmed its fiscal 2026 adjusted earnings before interest, tax, depreciation, and amortization (EBITDA) outlook of $62 million to $72 million, citing long-term opportunities tied to U.S. cannabis rescheduling and medical expansion.Chairman and CEO Irwin D. Simon told analysts on a call on Thursday that Tilray is currently operating at an annualized run rate of about $150 million, driven mainly by international markets. Simon also added that Europe, particularly Germany, the U.K., and Poland, represents a significant growth opportunity.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the intraday gains, retail sentiment on Stocktwits for <a href="https://stocktwits.com/symbol/TLRY">TLRY</a> remained in the ‘bearish’ territory over the past 24 hours.<figure class="image"><img src="https://news.stocktwits-cdn.com/TLRY_jpg_463814541d.webp" alt="TLRY.jpg" width="922" height="96"><figcaption>&nbsp;</figcaption></figure>However, some users were bullish, with one highlighting Tilray’s strong results.<stembedurl>https://stocktwits.com/Mlitton13/message/641317326</stembedurl>The stock has declined 24% over the past year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-oklo-stock-surged-premarket-today-meta-deal/cmU2fX3R4dI">OKLO Stock Surged 20% In Premarket Today – What’s The Meta Agreement About?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Tilray Brands logo is seen displayed on a smartphone and in the background.

TLRY Stock In Focus After Alliance Global Halves Price Target

Alliance Global cut TLRY’s target price to $10 from $20, citing limited visibility into the company’s long-term sales trajectory and cash flow.

Equity

Cannabis ETFs Soar Double-Digits on Friday: Here's Why

Cannabis ETFs explode on reform buzz. CNBS, WEED, MSOS and MJ jumped double-digits on Dec. 12, 2025 as Trump reportedly weighs reclassifying marijuana, boosting optimism.

Cannabis plants grow in the greenhouse at Vireo Health's medical marijuana cultivation facility, August 19, 2016 in Johnstown, New York. (Photo by Drew Angerer/Getty Images)

Trump Moves A Step Closer To Reclassifying Marijuana As A Less Dangerous Drug — A Breakout Moment For Weed Industry?

The cannabis industry is enjoying renewed momentum under Trump, whose administration has adopted a notably more accommodative approach toward the drug and its related products.

<ul class="summary-bullets"><li>Bloomberg reported that the Centers for Medicare &amp; Medicaid Services (CMS), which runs the Medicare program, is planning an initiative that would make some U.S. Medicare patients eligible for CBD coverage.&nbsp;</li><li>MSOS and YOLO, two key cannabis sector-focused funds, gained 3.4% and 2.7%, respectively.</li><li>The Trump administration seems to be backing cannabis as an industry, following its previous comments regarding CBD and reclassifying marijuana.</li></ul>Cannabis&nbsp;stocks advanced on Wednesday following a report speculating that certain U.S Medicare patients could soon be eligible to receive coverage for CBD under a new initiative.CBD, or cannabidiol, is a compound found in cannabis and used to treat sleep disorders, anxiety, pain, and inflammation. Some research suggests it may also treat cancer symptoms. The drug is sold as gummies, pet treats, and skincare supplements.<h2 class="st-heading-2">Cannabis Stocks Rally</h2>Tilray Brands’ shares rose 4.8%, while the over-the-counter stocks of Curaleaf Holdings, Trulieve Cannabis, and Green Thumb Industries gained between 2% to 5.6%. Shares of Innovative Industrial Properties, a real estate investment trust (REIT) that buys and leases specialized cannabis cultivation facilities, rose 1.1%.On Stocktwits, the retail sentiment for&nbsp;<a href="https://stocktwits.com/symbol/TLRY">TLRY</a> shifted to ‘extremely bullish’ from ‘bullish,’ while that for&nbsp;<a href="https://stocktwits.com/symbol/CURLF">CURLF</a> shifted to ‘bullish’ from ‘neutral.’ The sentiment was ‘bullish’ for&nbsp;<a href="https://stocktwits.com/symbol/GTBIF">GTBIF</a>, and ‘bearish’ for&nbsp;<a href="https://stocktwits.com/symbol/GTBIF">TCNNF</a> and&nbsp;<a href="https://stocktwits.com/symbol/IIPR">IIPR</a> as of the last reading.&nbsp;The&nbsp;<a href="https://stocktwits.com/symbol/MSOS">AdvisorShares Pure US Cannabis ETF (MSOS)</a>, which tracks U.S. cannabis companies exclusively, and the&nbsp;<a href="https://stocktwits.com/symbol/YOLO">AdvisorShares Pure Cannabis ETF (YOLO)</a>, which also tracks overseas companies and cannabis-adjacent businesses, rose 3.4% and 2.7%, respectively.<h2 class="st-heading-2">CMS Initaitive</h2>The rally came after Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-11-26/medicare-to-test-making-cbd-treatment-available-for-seniors">reported</a> that the Centers for Medicare &amp; Medicaid Services (CMS) is planning an initiative that would make some U.S. Medicare patients eligible for CBD coverage.&nbsp;Details of the proposed program aren’t available, but an early version of the plan focused on seniors in oncology and palliative care settings, according to a summary viewed by the news agency.Unnamed sources told Bloomberg that Howard Kessler, a payments financier who has advocated for expanded CBD access, met with Health and Human Services Secretary Robert F. Kennedy Jr. about the issue last month<h2 class="st-heading-2">A Trump Boost?</h2>The development comes close on the heels of President Donald Trump highlighting the potential benefits of cannabidiol in senior healthcare. Hemp-derived cannabidiol (CBD) could "revolutionize senior healthcare" by slowing disease progression and serving as an alternative to prescription drugs, Trump had&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tilray-canopy-growth-cannabis-stocks-lose-high-premarket-after-surge-triggered-by-trumps-post/chDDTJ9R3BB">said</a> in a video post in September.The previous month, Trump said his administration was weighing a move to reclassify marijuana as a less dangerous drug under federal law.That said, doubts over cannabis efficacy in healthcare remain. A&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2836267">recent study</a> funded by the Food and Drug Administration suggested that prolonged use of CBD may cause liver toxicity, while other research suggests it can interfere with other medications, harm male reproductive health, and pose potential risks to children and pregnant women.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/holiday-shopping-could-soar-to-a-record-1-trillion-this-year-with-online-spending-blasting-to-new-highs/cL5eLqVREW6">Holiday Shopping Could Soar To A Record $1 Trillion This Year, With Online Spending Blasting To New Highs</a>

Tilray, IIPR, Trulieve, Other Cannabis Stocks Rally On Report Of Government Considering Adding CBD Treatment For Medicare Patients  

The development comes close on the heels of President Donald Trump highlighting the potential benefits of cannabidiol in senior healthcare. 

The Zacks Analyst Blog Highlights MSOS, CNBS, WEED, MJ and YOLO

Zacks Analyst Blog highlights MSOS, CNBS, WEED, MJ, and YOLO as marijuana ETFs soar over 100% in three months on U.S. legalization hopes and investor optimism.

From Loss to Lift-Off: Marijuana ETFs Rebound on Legalization Prospects 

Marijuana ETFs, such as WEED, MSOS, and CNBS, are rebounding as hopes for rescheduling boost investor optimism. 

Top-Performing ETFs of Last Week

ETFs tied to cannabis, Ethereum and Chinese tech stocks topped last week's winners list. Top performers were KSTR, YOLO, ARKZ, CHIQ and CNXT.

Cannabis ETFs Soar as Trump Mulls Over Marijuana Reclassification

Cannabis ETFs like WEED, CNBS and MJ surge after Trump confirmed that his administration is weighing marijuana's move from Schedule I to Schedule III.


Nasdaq-listed shares of Canopy Growth Corp. (CGC) fell 12% in pre-market trading on Friday after the cannabis company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.canopygrowth.com/investors/news-releases/canopy-growth-reports-fourth-quarter-and-fiscal-year-2025-financial-results/">reported</a> wider-than-expected fourth-quarter (Q4) loss.The company’s fourth quarter revenue fell 11% year-on-year (YoY) to C$65.03 million ($47.16 million), below an analyst estimate of C$70.87 million, according to Finchat data.The company attributed the drop to a decline in net revenue from its international markets cannabis, and Storz &amp; Bickel segments.In Canada, cannabis net revenue was C$40 million in the quarter, marking an increase of 4% YoY. However, across international markets, the revenue declined 35% YoY to C$8 million, owing to a decline in medical cannabis sales in Poland and Australia, the company said.Storz and Bickel, meanwhile, delivered net revenue of C$17 million in the quarter, a decrease of 23% YoY, owing to softer consumer demand for its devices. Storz and Bickel designs vaporizers for combustion-free vaporization and inhalation of dry herbs.The company’s gross margin fell by 500 basis points to 16% in the quarter, and it reported an adjusted loss before interest, taxes, depreciation, and amortisation (EBITDA) of C$9 million. Analysts had only expected a loss of C$3.13 million.The company’s total debt, however, decreased to C$304 million as of March 31, compared to C$597 million on the corresponding date of 2024.The company said on Friday that it plans to continue to focus on accelerating growth in global medical cannabis, improving commercial execution, and profitability in Canada’s adult-use cannabis market. The company also said that cost actions are underway and it expects annualized savings of at least C$20 million over the next 12 to 18 months.CFO Judy Hong also said that the company is committed to achieving positive adjusted EBITDA in the “near-term,” without specifying a timeline.On Stocktwits, retail sentiment around Canopy Growth stayed within the ‘bearish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:627/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_30_at_8_59_37_AM_png_cf8cb9e0cf.webp" alt="CGC's Sentiment Meter and Message Volume as of 8:15 a.m. ET on May 30, 2025 | Source: Stocktwits" width="627" height="64"><figcaption>CGC's Sentiment Meter and Message Volume as of 8:15 a.m. ET on May 30, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user termed the Q4 earnings reports “a pretty big let down.” &nbsp;<stembedurl>https://stocktwits.com/JustAGlitchBTMFD/message/616291899</stembedurl><a href="https://stocktwits.com/symbol/CGC">CGC stock </a>is down by about 41% this year and by about 80% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/zymeworks-drug-gets-conditional-approval-for-biliary-tract-cancer-in-china/ch0Mun4RbMx">Zymeworks’ Drug Gets Conditional Approval For Biliary Tract Cancer Treatment In China: Retail Sentiment Refuses To Budge</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.(Exchange Rate: I Canadian Dollar= 0.73 US Dollar)

A cart full of bagged marijuana is rolled through the corridors at the Canopy Growth Corporation headquarters in Smiths Falls, Ontario, on May 15, 2019. (Photo by Lane Turner/The Boston Globe via Getty Images)

Canopy Growth Stock Drops Pre-Market After Disappointing Q4 Earnings: Retail Terms It ‘A Pretty Big Let Down’

CFO Judy Hong said the company is committed to achieving positive adjusted EBITDA in the “near-term,” without specifying a timeline.

This REIT ETF Just Hit a 52-Week Low. Here’s Why It’s Time to Buy.

Twenty-two ETFs hit 52-week highs, and 17 hit 52-week lows on Tuesday. One of the ETFs hitting a 52-week low was an Invesco REIT that’s worth considering for income-focused investors. Here’s why.

Advisorshares Trust - AdvisorShares Pure Cannabis ETF

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

Current Price	$3.28
Prev Close	$3.36
Open	$3.33
Dividend Yield	N/A
50-Day Moving Average	$3.15
Beta	N/A
Avg. Volume	240,913.27
PE Ratio	N/A

52-Week High	$4.53
52-Week Low	$1.45
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

YOLO
AdvisorShares Pure Cannabis ETF

Feed

News

Sentiment

Fundamentals

Info

Latest YOLO News

YOLOAdvisorShares Pure Cannabis ETF